Hyperemesis Gravidarum Genes: Largest GWAS Study

Quick Summary

• Largest GWAS identifies 10 genes linked to hyperemesis gravidarum (HG)
• GDF15 remains the strongest genetic driver of severe pregnancy sickness
• Six newly identified genes expand understanding of hormonal, metabolic, and neurological pathways
• Findings open doors for targeted therapies and personalized treatment approaches

What Causes Severe Pregnancy Sickness? New Genetic Insights Explained

A large-scale genetic study has advanced understanding of hyperemesis gravidarum (HG), a severe pregnancy sickness affecting about 2% of women. Researchers from the Keck School of Medicine of USC analyzed data from over 10,000 cases and 460,000 controls across diverse populations, making it the most comprehensive study to date.

The findings confirm that GDF15, a hormone-encoding gene, plays a central role. Women with lower pre-pregnancy exposure to GDF15 are more sensitive to its rise during pregnancy, leading to severe symptoms, while higher baseline exposure is linked to milder cases.

Researchers also identified nine additional genes, including GFRAL, IGFBP7, and PGR, involved in placental development and hormone signaling. Six of these are newly linked to HG, reinforcing its strong biological and genetic basis rather than psychological causes.

Which New Genes Are Linked to Hyperemesis Gravidarum?

The newly identified genes, FSHB, TCF7L2, SLITRK1, SYN3, IGSF11, and CDH9, highlight multiple biological pathways involved in HG:

• Hormonal regulation: FSHB influences reproductive hormone balance
• Metabolism and insulin signaling: TCF7L2 is linked to type 2 and gestational diabetes
• Neurological adaptation: Genes like SLITRK1 and SYN3 suggest a role in brain plasticity and learned food aversions
• Appetite and nausea pathways: Several genes affect gut-brain signaling

These findings suggest that HG is a multifactorial condition, involving hormonal sensitivity, metabolic processes, and neurological responses.

Can Genetic Findings Improve Hyperemesis Gravidarum Treatment?

Current treatments for HG, including ondansetron, often provide only partial relief. The discovery of new genetic targets opens the door to more precise, individualized treatment approaches.

Researchers are now evaluating metformin in clinical trials, as it may increase GDF15 levels before pregnancy and reduce symptom severity. Some identified genes are also linked to adverse outcomes like preeclampsia and shorter gestation, highlighting the need for early detection and management.

What This Means for Clinical Practice

The identification of new genetic drivers behind hyperemesis gravidarum (HG) marks an important shift in how clinicians understand and approach severe pregnancy sickness. With evidence pointing to hormonal sensitivity, metabolic pathways, and neurological adaptation, HG should be recognized as a biologically driven condition requiring structured clinical management.

For obstetricians, gynecologists, and allied healthcare professionals, these findings highlight the need to:

• Consider early risk identification in patients with prior HG history
• Stay informed on emerging therapeutic strategies, including repurposed drugs like metformin
• Integrate genetic insights into personalized care pathways

As research continues to shape clinical protocols, staying current is essential for improving maternal and fetal outcomes.

Explore upcoming CME Conferences & Online Courses in Obstetrics & Gynecology.

Stay updated on the latest advancements and evidence-based practices in maternal health.

Source:

Keck School of Medicine of USC